DGIdb - BCL2 Gene Record

BCL2 596 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

596
BCL2, APOPTOSIS REGULATOR
BCL2
Bcl-2
PPP1R50
151430
990
ENSG00000171791
OTTHUMG00000132791
P10415
BCL2_HUMAN
APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415]
Apoptosis regulator Bcl-2
PA25302
BCL2 apoptosis regulator
T31309
59

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Domain
Interpro Name	Apoptosis regulator, Bcl-2, BH
Uniprot Status	Swiss-Prot
Interpro Short Name	Bcl2_BH
Interpro Acc	IPR000712
Target Class	other
Target Subclass	regulator of apoptosis
Target Subclass	Other
Transmembrane Helix Count	1
Target Main Class	Other
Gene Biotype	PROTEIN_CODING

(16 More Sources)

Gene Categories: Category Details

DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Kuo et al., 1999, Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis., Mol. Pharmacol.
Osterreicher et al., 2001, Apoptosis and bcl-2 expression in irradiated lungs and the effect of pentoxifylline., Acta Medica (Hradec Kralove)
Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
Abulwerdi FA et al., 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation., J Med Chem
Ran et al., 2005, [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]., Di Yi Jun Yi Da Xue Xue Bao
Salleh et al., 2004, Gene expression profiling of p53(+/-) knockout and wild-type mice following diethylstilbestrol administration., IUBMB Life
McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
Pérez-Galán P et al., 2007, The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak., Blood
Li J et al., 2008, A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells., Cancer Chemother Pharmacol
Davids et al., 2013, ABT-199: taking dead aim at BCL-2., Cancer Cell
Souers et al., 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets., Nat. Med.
Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica
Birkinshaw RW et al., 2019, Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations., Nat Commun
Blombery P et al., 2020, Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax., Blood
Lucas F et al., 2020, Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations., Blood
Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov
Blombery P et al., 2019, Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma., Br J Haematol
King AC et al., 2017, Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies., Ann Pharmacother
Mueller et al., 2003, Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer., Cancer Res.
Baltaci et al., 2001, P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours., BJU Int.
Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.
Fisher et al., 1993, bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways., Cancer Res.
Peters et al., 2000, Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed., Eur. J. Cancer
Yoshino et al., 2006, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy., Clin. Cancer Res.
Matsuyoshi et al., 2006, Bcl-2 phosphorylation has pathological significance in human breast cancer., Pathobiology
Gan et al., 2006, Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors., Pharm. Res.
Thomadaki et al., 2006, Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS., Biol. Chem.
Zhang et al., 2007, Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells., Int. J. Cancer
Ng et al., 2000, Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines., Anal. Quant. Cytol. Histol.
Chi et al., 2001, A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer., Clin. Cancer Res.
Heaton et al., 2004, Vitamin E amelioration of ethanol neurotoxicity involves modulation of apoptotis-related protein levels in neonatal rat cerebellar granule cells., Brain Res. Dev. Brain Res.
Petrylak, 2005, Chemotherapy for androgen-independent prostate cancer., World J Urol
Marshall et al., 2004, A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors., Ann. Oncol.
Inoue et al., 2005, Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer., Oncol. Rep.
Miyoshi et al., 2005, [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]., Nippon Rinsho
Gligorov et al., 2004, Preclinical pharmacology of the taxanes: implications of the differences., Oncologist
Magi-Galluzzi et al., 2007, Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study., Cancer
Lin et al., 2006, In vitro folate deficiency induces apoptosis by a p53, Fas (Apo-1, CD95) independent, bcl-2 related mechanism in phytohaemagglutinin-stimulated human peripheral blood lymphocytes., Br. J. Nutr.
Loberg RD et al., 2007, In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration., Neoplasia
Shaker OG et al., 2011, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients., Clin Chim Acta
Panasiuk et al., 2005, [The apoptosis of hepatic tissues in hepatitis C]., Przegl Epidemiol
Anatol et al., 2005, Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy., World J. Gastroenterol.
Pisani et al., 1997, In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts., Ann. Hematol.
Lin et al., 2005, Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells., Cancer Lett.
Malugin et al., HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function., Mol. Pharm.
Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem
Jesmin et al., 2006, Effects of dual endothelin receptor antagonist on antiapoptotic marker Bcl-2 expression in streptozotocin-induced diabetic rats., Exp. Biol. Med. (Maywood)
Serafin et al., Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines., Urol. Oncol.
Chow et al., 2003, The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells., Breast Cancer Res. Treat.
Tetè et al., 1999, The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin., Minerva Stomatol
Piattelli et al., 1999, bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study., Oral Oncol.
Ballestrero et al., 2004, Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells., Clin. Cancer Res.
Emir et al., 2005, Beneficial effect of methylprednisolone on cardiac myocytes in a rat model of severe brain injury., Tohoku J. Exp. Med.
Adişen et al., 2006, The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis., J Eur Acad Dermatol Venereol
Weller et al., 1998, Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses., Int. J. Cancer

OBLIMERSEN BCL2

Interaction Score: 4.31

Interaction Types & Directionality:

antisense oligonucleotide (inhibitory)

Interaction Info:

Trial Name Genasense

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial TTD
BEAUVERICIN BCL2

Interaction Score: 2.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16297711

Sources:
NCI
VENETOCLAX BCL2

Interaction Score: 1.7

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Direct Interaction yes

PMIDs:
23410971 23291630 31004028 31160589 31951646 32232486 30514704 31234236 28056525

Sources:
MyCancerGenome ChemblInteractions CIViC TTD
PROTUBOXEPIN A BCL2

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22595423

Sources:
DTC
OBATOCLAX BCL2

Interaction Score: 1.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name obatoclax, GX15-070

Novel drug target Established target

PMIDs:
17227835 17505826

Sources:
TALC TdgClinicalTrial TTD
ISOSORBIDE BCL2

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AT-101

Novel drug target Established target

PMIDs:
18084610

Sources:
TdgClinicalTrial
HYPOXANTHINE BCL2

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16611376

Sources:
NCI
TESETAXEL BCL2

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tesetaxel

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
ANG1005 BCL2

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ANG1005

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
NAVITOCLAX BCL2

Interaction Score: 0.6

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Notes

PMIDs:
24749893

Sources:
TALC DTC ChemblInteractions TTD
CILENGITIDE BCL2

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12154028

Sources:
NCI
MILATAXEL BCL2

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name milataxel, MAC-321

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
RALTITREXED BCL2

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10785598

Sources:
NCI
ISOTRETINOIN BCL2

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10638174 10621853

Sources:
NCI
TENIPOSIDE BCL2

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9842975

Sources:
NCI
ORTATAXEL BCL2

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ortataxel

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
TAZAROTENE BCL2

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16109552

Sources:
NCI
METHYLPREDNISOLONE BCL2

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16141680 16684279

Sources:
NCI
EDARAVONE BCL2

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ESTRAMUSTINE BCL2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15869997

Sources:
NCI
VITAMIN E BCL2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15158075

Sources:
NCI
OBATOCLAX MESYLATE BCL2

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
RIBAVIRIN BCL2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21159314 16190549 15902734

Sources:
NCI PharmGKB
PHENYLBUTANOIC ACID BCL2

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10696460

Sources:
NCI
FLOXURIDINE BCL2

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8324744

Sources:
NCI
HYDROQUINONE BCL2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10220568

Sources:
NCI
DOCETAXEL BCL2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name BIND-014

Novel drug target Established target

Trial Name Docetaxel

PMIDs:
23963862 15685445 15277270 15643508 15714982 15161985 17674353

Sources:
TdgClinicalTrial PharmGKB
PACLITAXEL BCL2

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Abraxane

Novel drug target Established target

Trial Name AI-850

PMIDs:
23963862 17062688 17119350 16741658 16895478 17230521

Sources:
TdgClinicalTrial ClearityFoundationClinicalTrial TEND PharmGKB TTD
ERYTHROMYCIN BCL2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17007374

Sources:
NCI
OXALIPLATIN BCL2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977850

Sources:
ClearityFoundationBiomarkers NCI
TRETINOIN BCL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9402847

Sources:
NCI
DIETHYLSTILBESTROL BCL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15545218

Sources:
NCI
EPIRUBICIN BCL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14503796

Sources:
NCI
PENTOXIFYLLINE BCL2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11836847

Sources:
NCI
ETOPOSIDE BCL2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977850 11350408

Sources:
NCI
MITOXANTRONE BCL2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11751483

Sources:
NCI
STREPTOZOCIN BCL2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16741044

Sources:
NCI
CARBOPLATIN BCL2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
ClearityFoundationBiomarkers PharmGKB
CISPLATIN BCL2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12543810 11350408

Sources:
ClearityFoundationBiomarkers NCI
DOXORUBICIN BCL2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16749867

Sources:
NCI
GOSSYPOL BCL2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
VINCRISTINE BCL2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
BORTEZOMIB BCL2

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Ensembl: ENSG00000171791
- Version: 101_38
Alternate Names:

BCL2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P10415
- Version: January-2014
Alternate Names:

BCL2 Gene Symbol

Gene Info:

Target Class other

Target Subclass regulator of apoptosis

Publications:
RussLampel: ENSG00000171791
- Version: 26-July-2011
Alternate Names:

APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415] Description

ENSG00000171791 Ensembl Gene Id

BCL2 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P10415
- Version: 11-September-2012
Alternate Names:

ENSG00000171791 Ensembl Gene Id

596 Entrez Gene Id

BCL2_HUMAN Uniprot Id

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Interpro Type Domain

Interpro Name Apoptosis regulator, Bcl-2, BH

Gene Categories:

DRUGGABLE GENOME

Publications:
TEND: P10415
- Version: 01-August-2011
Alternate Names:

596 Entrez Gene Id

ENSG00000171791 Ensembl Gene Id

P10415 Uniprot Accession

Gene Info:

Target Subclass Other

Transmembrane Helix Count 1

Target Main Class Other

Publications:

PharmGKB: BCL2

Version: 18-August-2020

Alternate Names:

PA25302 PharmGKB ID

Gene Info:

Publications:

McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res

Shaker OG et al., 2011, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients., Clin Chim Acta

CIViC: BCL2

Version: 14-September-2020

Alternate Names:

596 Entrez Gene ID

59 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Tausch E et al., 2019, Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia., Haematologica

Blombery P et al., 2019, Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov

Blombery P et al., 2020, Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax., Blood

NCI: BCL2

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Kuo et al., 1999, Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis., Mol. Pharmacol.

Ran et al., 2005, [Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance]., Di Yi Jun Yi Da Xue Xue Bao

Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.

DTC: BCL2

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Abulwerdi FA et al., 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation., J Med Chem

Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem

MyCancerGenome: BCL2
- Version: 20-Jun-2017
Alternate Names:

BCL2 MyCancerGenome Gene Symbol

BCL2 MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: BCL2
- Version: chembl_23
Alternate Names:

BCL2 GENE_SYMBOL

Apoptosis regulator Bcl-2 UNIPROT

Gene Info:

Publications:
TALC: BCL-2
- Version: 12-May-2016
Alternate Names:

BCL-2 Gene Symbol

Gene Info:

Publications:
HingoraniCasas: ENSG00000171791
- Version: 31-May-2017
Alternate Names:

ENSG00000171791 Gene Symbol

BCL2 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: BCL2
- Version: 11-November-2018
Alternate Names:

BCL2 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Apoptosis regulator Bcl-2
- Version: 2020.06.01
Alternate Names:

BCL-2 TTD Gene Abbreviation

T31309 TTD Target ID

Gene Info:

Publications:
MskImpact: BCL2
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationClinicalTrial: BCL2
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
ClearityFoundationBiomarkers: BCL2
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: BCL2
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: BCL2
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Mechanism of Interaction	Apoptosis regulator Bcl-2 inhibitor
Direct Interaction	yes

Notes
Trial Name	obatoclax, GX15-070
Novel drug target	Established target

Trial Name	milataxel, MAC-321
Novel drug target	Established target

Trial Name	BIND-014
Novel drug target	Established target
Trial Name	Docetaxel

Trial Name	Abraxane
Novel drug target	Established target
Trial Name	AI-850

APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415]	Description
ENSG00000171791	Ensembl Gene Id
BCL2	Display Id

ENSG00000171791	Ensembl Gene Id
596	Entrez Gene Id
BCL2_HUMAN	Uniprot Id

BCL2	MyCancerGenome Gene Symbol
BCL2	MyCancerGenome Reported Gene Name

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

BCL2 Gene Record

BCL2 596 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antisense oligonucleotide (inhibitory)

Interaction Info: Trial Name Genasense Novel drug target Established target Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16297711

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor Direct Interaction yes

PMIDs: 23410971 23291630 31004028 31160589 31951646 32232486 30514704 31234236 28056525

Sources: MyCancerGenome ChemblInteractions CIViC TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22595423

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name obatoclax, GX15-070 Novel drug target Established target

PMIDs: 17227835 17505826

Sources: TALC TdgClinicalTrial TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name AT-101 Novel drug target Established target

PMIDs: 18084610

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16611376

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name tesetaxel Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Trial Name ANG1005 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor Notes

PMIDs: 24749893

Sources: TALC DTC ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12154028

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name milataxel, MAC-321 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10785598

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10638174 10621853

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9842975

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name ortataxel Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16109552

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16141680 16684279

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

antisense oligonucleotide (inhibitory)

Interaction Info:

Trial Name Genasense

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

PMIDs:
16297711

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Direct Interaction yes

PMIDs:
23410971 23291630 31004028 31160589 31951646 32232486 30514704 31234236 28056525

Sources:
MyCancerGenome ChemblInteractions CIViC TTD

Interaction Types & Directionality:

n/a

PMIDs:
22595423

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name obatoclax, GX15-070

Novel drug target Established target

PMIDs:
17227835 17505826

Sources:
TALC TdgClinicalTrial TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AT-101

Novel drug target Established target

PMIDs:
18084610

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
16611376

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tesetaxel

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ANG1005

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Notes

PMIDs:
24749893

Sources:
TALC DTC ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
12154028

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name milataxel, MAC-321

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
10785598

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10638174 10621853

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9842975

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ortataxel

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
16109552

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16141680 16684279

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
15869997

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15158075

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Apoptosis regulator Bcl-2 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
21159314 16190549 15902734

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a